{"id":"phenacemide","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL918","moleculeType":"Small molecule","molecularWeight":"178.19"},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:37:33.081093","allNames":"phenurone","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Sodium channel protein type 1 subunit alpha","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:37:41.612Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Epilepsy","diseaseId":"epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy characterized by intractable complex partial seizures","diseaseId":"epilepsy-characterized-by-intractable-complex-partial-seizures","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":33,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Phenurone","genericName":"PHENACEMIDE","companyName":"Abbvie","companyId":"","modality":"Small molecule","firstApprovalDate":"1951","aiSummary":"Phenurone (PHENACEMIDE) is a small molecule drug developed by Abbvie, targeting the sodium channel protein type 1 subunit alpha. It is classified as a phenacemide and was FDA-approved in 1951 for the treatment of epilepsy, specifically intractable complex partial seizures. As an off-patent medication, it is no longer protected by active patents, and there are currently no generic manufacturers. Phenurone works by modulating the activity of sodium channels in the brain, which helps to reduce the frequency and severity of seizures. Despite its long history, key safety considerations and pharmacokinetic parameters, such as half-life and bioavailability, remain unknown.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}